GlassScriptPhysician profile
Aamer Habib
NPI 1922128560
$9,475.73
in general payments reported to CMS, 2019-2025
59 companies · $1,873 in 2025
The $1,873 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,534 · 2020: $153 · 2021: $181 · 2022: $1,043 · 2023: $1,813 · 2024: $2,877 · 2025: $1,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,319 · Education: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,318.77 |
| Education | $244.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $898.02 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $610.74 | 2019-2024 | Qelbree |
| Lilly USA, LLC | $587.13 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Genentech USA, INC. | $470.89 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Novartis Pharmaceuticals Corporation | $419.45 | 2019-2025 | |
| Catalyst Pharmaceuticals, INC. | $405.43 | 2022-2025 | Fycompa |
| Lundbeck LLC | $396.26 | 2019-2025 | Vyepti |
| Biogen, INC. | $351.20 | 2019-2025 | Vumerity, Tysabri |
| Teva Pharmaceuticals USA, INC. | $346.96 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Alexion Pharmaceuticals, INC. | $338.63 | 2019-2024 | Ultomiris, Soliris |
| Eisai INC. | $321.11 | 2023-2025 | |
| Pfizer INC. | $306.49 | 2019-2025 | |
| Ucb, INC. | $289.62 | 2019-2025 | Zilbrysq, Briviact, Rystiggo |
| Sk Life Science, INC. | $267.07 | 2020-2025 | |
| Amgen INC. | $240.28 | 2019-2025 | Uplizna, Aimovig |
Show all 58 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aamer Habib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.